PEGylated PLGA nanoparticles for the improved delivery of doxorubicin
about
Strategies to target tumors using nanodelivery systems based on biodegradable polymers, aspects of intellectual property, and marketStealth Properties to Improve Therapeutic Efficacy of Drug NanocarriersMagnetic core-shell nanoparticles for drug delivery by nebulizationBeta-cyclodextrin-centered star-shaped amphiphilic polymers for doxorubicin delivery.Preparation, Optimization and Toxicity Evaluation of (SPION-PLGA) ±PEG Nanoparticles Loaded with Gemcitabine as a Multifunctional Nanoparticle for Therapeutic and Diagnostic Applications.Encapsulation in nanoparticles improves anti-cancer efficacy of carboplatin.Conjugation of pH-responsive nanoparticles to neural stem cells improves intratumoral therapy.Docetaxel Loaded PEG-PLGA Nanoparticles: Optimized Drug Loading, In-vitro Cytotoxicity and In-vivo Antitumor Effect.Exploiting the tumor phenotype using biodegradable submicron carriers of chemotherapeutic drugs.Nanoparticles deliver triplex-forming PNAs for site-specific genomic recombination in CD34+ human hematopoietic progenitors.Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer.Radiolabeling of poly(lactic-co-glycolic acid) (PLGA) nanoparticles with biotinylated F-18 prosthetic groups and imaging of their delivery to the brain with positron emission tomography.Phase separation behavior of mixed lipid systems at neutral and low pH: coarse-grained simulations with DMD/LIME.Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumorsComparative Cytotoxic Evaluation of Free and Sodium Alginate Nanoparticle-Encapsulated ICD-85 on Primary Lamb Kidney CellsPEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma.Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism.Evaluation of triblock copolymeric micelles of δ- valerolactone and poly (ethylene glycol) as a competent vector for doxorubicin delivery against cancerCationic albumin nanoparticles for enhanced drug delivery to treat breast cancer: preparation and in vitro assessment.Microtubule targeted therapeutics loaded polymeric assembled nanospheres for potentiation of antineoplastic activity.The impact of nanoparticle ligand density on dendritic-cell targeted vaccines.LC-MS/MS method development for quantification of doxorubicin and its metabolite 13-hydroxy doxorubicin in mice biological matrices: Application to a pharmaco-delivery study.Co-nanoencapsulation of magnetic nanoparticles and selol for breast tumor treatment: in vitro evaluation of cytotoxicity and magnetohyperthermia efficacyFactors determining the stability, size distribution, and cellular accumulation of small, monodisperse chitosan nanoparticles as candidate vectors for anticancer drug delivery: application to the passive encapsulation of [(14)C]-doxorubicin.Ibuprofen delivered by poly(lactic-co-glycolic acid) (PLGA) nanoparticles to human gastric cancer cells exerts antiproliferative activity at very low concentrationsCell penetrating peptide-modified poly(lactic-co-glycolic acid) nanoparticles with enhanced cell internalization.PEGylation as a strategy for improving nanoparticle-based drug and gene deliveryDrug release kinetics, cell uptake, and tumor toxicity of hybrid VVVVVVKK peptide-assembled polylactide nanoparticles.Systemic delivery of blood-brain barrier-targeted polymeric nanoparticles enhances delivery to brain tissueConfiguration-dependent Presentation of Multivalent IL-15:IL-15Rα Enhances the Antigen-specific T Cell Response and Anti-tumor ImmunitySystemic delivery of triplex-forming PNA and donor DNA by nanoparticles mediates site-specific genome editing of human hematopoietic cells in vivo.Enhancement of surface ligand display on PLGA nanoparticles with amphiphilic ligand conjugatesEfficient intravesical therapy of bladder cancer with cationic doxorubicin nanoassemblies.Doxorubicin and resveratrol co-delivery nanoparticle to overcome doxorubicin resistance.Poly(omega-pentadecalactone-co-butylene-co-succinate) nanoparticles as biodegradable carriers for camptothecin delivery.Anticancer Activity of Nanoparticles Based on PLGA and its Co-polymer: In-vitro Evaluation.A Micelle Self-Assembled from Doxorubicin-Arabinoxylan Conjugates with pH-Cleavable Bond for Synergistic Antitumor TherapyDoxorubicin-loaded platelets as a smart drug delivery system: An improved therapy for lymphomaA lupus anti-DNA autoantibody mediates autocatalytic, targeted delivery of nanoparticles to tumors.Block Copolymer-Encapsulated CaWO4 Nanoparticles: Synthesis, Formulation, and Characterization.
P2860
Q27015050-440F0D86-6FB2-49EB-B232-56000923B019Q27496024-91D2E3D9-7D90-4C2B-9A8C-4E788E7FCE36Q28393991-861E6F9D-753C-47CF-BBBE-D9C292E3AE24Q33530676-7A283A61-0846-4367-8EFA-C4E247B3DE82Q33652198-5A0E3F66-17FC-4E7E-B8C2-D1A684484D57Q33962540-11CB1D73-CCE9-4304-947D-8BFD66F308E8Q34145424-7F3A34C1-2315-4DE6-8853-069FC721C013Q34256302-4ABB1DDD-C3D2-4879-A0D8-76CDDBCBF14AQ34284213-8815DC15-0D0A-4693-8FF2-245C015EB77AQ34473283-A51C8C14-F03C-4600-B8BC-9D90695F9E2BQ34680322-01711011-0D6C-441F-B65A-BB8D6201D0E7Q34764435-72B3E79A-7DB1-46BD-BF1C-9EC4AB06D938Q35027166-14F519F6-4DF2-4794-995A-912790EA82A5Q35052416-77EB9F74-CC2C-43DC-B5C5-EF986395045BQ35272662-C9B3BD42-C33A-4CC5-8371-8C651B9F3B44Q35377803-D127422C-99A9-415E-B29F-D58A48E15683Q35439618-44087A61-A042-4531-812A-3ECE39F5BC92Q35541049-AD9B771B-C8CA-44F0-972E-C7DAEC3C0672Q35609201-FE6AC023-94A8-4E90-B303-09A14AD3650FQ35893673-59F7D35B-7745-42CB-BA26-B6DF5F22216EQ36062758-930F84F6-F6A1-4278-92A7-872CC5DFC25CQ36156185-1510687A-B22E-4DCD-B70B-200657E07B61Q36308718-5AF887BE-B268-4C6C-B787-01D7D6B6A65BQ36391000-10930452-0EC0-4E40-A99C-4C2B02668E2FQ36398230-B3CCBE6C-D4C8-4CE1-A36E-381C2CFDC62EQ36414890-FAF7867F-D402-4CBB-8C07-FE17A9C34475Q36703361-540F7DAC-4AB5-4D0B-9552-269445687AE6Q36767228-0778C563-9388-4DCC-A87E-1212369607E2Q36881132-8E517D8A-B042-4C1B-8BB7-4ED7EB6FCD59Q36884768-5FB59AF7-13D2-4F3F-B0D5-8D2DE76FBA81Q37019421-3C42C74A-E995-4041-8F70-7FE4A00ACE11Q37238542-992BFC99-2C6B-4D13-88FF-896046C011ECQ37249063-7EC900A8-8B64-438B-BE0A-AB59789A132AQ37330473-5E101F9C-9444-44F2-BD0D-070497890024Q37415357-831EC413-F8D8-4BB3-A942-D269D4C3D019Q37576945-4847BC50-0A78-4764-B019-83B0A870250EQ37608021-AFDF4D58-8A7E-422A-AC2A-4A7DD0AE4A64Q37642601-11BADAA1-25B9-42AB-882A-4045A63DF282Q37644972-8EB4B380-9A91-41D1-B78A-317915079D8EQ37716113-4F13153C-873A-413F-A552-787AB4CDA3C3
P2860
PEGylated PLGA nanoparticles for the improved delivery of doxorubicin
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
PEGylated PLGA nanoparticles for the improved delivery of doxorubicin
@en
PEGylated PLGA nanoparticles for the improved delivery of doxorubicin.
@nl
type
label
PEGylated PLGA nanoparticles for the improved delivery of doxorubicin
@en
PEGylated PLGA nanoparticles for the improved delivery of doxorubicin.
@nl
prefLabel
PEGylated PLGA nanoparticles for the improved delivery of doxorubicin
@en
PEGylated PLGA nanoparticles for the improved delivery of doxorubicin.
@nl
P2093
P2860
P1476
PEGylated PLGA nanoparticles for the improved delivery of doxorubicin
@en
P2093
Carmen J Booth
Jason Park
Kerry S Russell
Peter M Fong
Tarek M Fahmy
W Mark Saltzman
P2860
P304
P356
10.1016/J.NANO.2009.02.002
P577
2009-03-31T00:00:00Z